• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实时分析破骨细胞吸收和融合动力学对骨吸收抑制剂的反应。

Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors.

机构信息

Department of Biochemistry and Molecular Biology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.

Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.

出版信息

Sci Rep. 2024 Mar 28;14(1):7358. doi: 10.1038/s41598-024-57526-9.

DOI:10.1038/s41598-024-57526-9
PMID:38548807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10978898/
Abstract

Cathepsin K (CatK), an essential collagenase in osteoclasts (OCs), is a potential therapeutic target for the treatment of osteoporosis. Using live-cell imaging, we monitored the bone resorptive behaviour of OCs during dose-dependent inhibition of CatK by an ectosteric (Tanshinone IIA sulfonate) and an active site inhibitor (odanacatib). CatK inhibition caused drastic reductions in the overall resorption speed of OCs. At IC CatK-inhibitor concentration, OCs reduced about 40% of their trench-forming capacity and at fourfold IC concentrations, a > 95% reduction was observed. The majority of CatK-inhibited OCs (~ 75%) were involved in resorption-migration-resorption episodes forming adjacent pits, while ~ 25% were stagnating OCs which remained associated with the same excavation. We also observed fusions of OCs during the resorption process both in control and inhibitor-treated conditions, which increased their resorption speeds by 30-50%. Inhibitor IC-concentrations increased OC-fusion by twofold. Nevertheless, more fusion could not counterweigh the overall loss of resorption activity by inhibitors. Using an activity-based probe, we demonstrated the presence of active CatK at the resorbing front in pits and trenches. In conclusion, our data document how OCs respond to CatK-inhibition with respect to movement, bone resorption activity, and their attempt to compensate for inhibition by activating fusion.

摘要

组织蛋白酶 K(CatK)是破骨细胞(OCs)中一种重要的胶原酶,是治疗骨质疏松症的潜在治疗靶点。通过活细胞成像,我们在 CatK 受到外切抑制剂(丹参酮 IIA 磺酸钠)和活性位点抑制剂(odanacatib)的浓度依赖性抑制时,监测了 OC 的骨吸收行为。CatK 抑制导致 OC 的整体吸收速度急剧下降。在 IC CatK-抑制剂浓度下,OC 减少了约 40%的沟槽形成能力,而在四倍 IC 浓度下,观察到超过 95%的减少。大多数被 CatK 抑制的 OC(75%)参与了形成相邻陷窝的吸收-迁移-吸收过程,而25%的停滞 OC 仍然与同一挖掘物相关联。我们还观察到在对照和抑制剂处理条件下 OC 在吸收过程中的融合,这使它们的吸收速度提高了 30-50%。抑制剂 IC 浓度使 OC 融合增加了两倍。然而,更多的融合并不能抵消抑制剂对整体吸收活性的丧失。使用基于活性的探针,我们证明了在坑和沟槽的吸收前沿存在活性 CatK。总之,我们的数据记录了 OC 如何对 CatK 抑制做出反应,包括运动、骨吸收活性以及它们通过激活融合来尝试补偿抑制的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/2ec9eba8c128/41598_2024_57526_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/4656a9e5d8cd/41598_2024_57526_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/b5d19a5b2073/41598_2024_57526_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/98b0dd0f71f1/41598_2024_57526_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/a9017dccd783/41598_2024_57526_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/0cb0854cdf39/41598_2024_57526_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/e95344a4d72d/41598_2024_57526_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/2ec9eba8c128/41598_2024_57526_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/4656a9e5d8cd/41598_2024_57526_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/b5d19a5b2073/41598_2024_57526_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/98b0dd0f71f1/41598_2024_57526_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/a9017dccd783/41598_2024_57526_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/0cb0854cdf39/41598_2024_57526_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/e95344a4d72d/41598_2024_57526_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dac/10978898/2ec9eba8c128/41598_2024_57526_Fig7_HTML.jpg

相似文献

1
Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors.实时分析破骨细胞吸收和融合动力学对骨吸收抑制剂的反应。
Sci Rep. 2024 Mar 28;14(1):7358. doi: 10.1038/s41598-024-57526-9.
2
Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.组织蛋白酶K抑制剂奥丹西普对骨吸收的抑制作用是完全可逆的。
Bone. 2014 Oct;67:269-80. doi: 10.1016/j.bone.2014.07.013. Epub 2014 Jul 16.
3
A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.组织蛋白酶 K 的轻度抑制反而会刺激培养的破骨细胞的吸收活性。
Calcif Tissue Int. 2019 Jan;104(1):92-101. doi: 10.1007/s00223-018-0472-7. Epub 2018 Sep 7.
4
Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone.丹参酮可选择性抑制组织蛋白酶 K 的胶原酶活性,为骨骼提供了一类新型的外消旋抗吸收药物。
Br J Pharmacol. 2018 Mar;175(6):902-923. doi: 10.1111/bph.14133. Epub 2018 Feb 9.
5
The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.组织蛋白酶 K 抑制剂odanacatib 对破骨细胞骨吸收和囊泡转运的影响。
Bone. 2011 Oct;49(4):623-35. doi: 10.1016/j.bone.2011.06.014. Epub 2011 Jun 22.
6
Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.研究用于骨质疏松症的组织蛋白酶 K 抑制剂odanacatib 的临床和转化药理学。
Br J Clin Pharmacol. 2019 Jun;85(6):1072-1083. doi: 10.1111/bcp.13869. Epub 2019 Mar 18.
7
Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.组织蛋白酶K的药理学抑制作用:绝经后骨质疏松症治疗的一种有前景的新方法。
Biochem Pharmacol. 2016 Oct 1;117:10-9. doi: 10.1016/j.bcp.2016.04.010. Epub 2016 Apr 19.
8
An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice.一种组织蛋白酶 K 外切抑制剂可抑制去卵巢小鼠的骨吸收。
J Bone Miner Res. 2017 Dec;32(12):2415-2430. doi: 10.1002/jbmr.3227. Epub 2017 Aug 25.
9
The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.破骨细胞的吸收装置支持溶酶体趋向性,并增加了组织蛋白酶 K 的碱性与非碱性抑制剂的效力。
Bone. 2010 May;46(5):1400-7. doi: 10.1016/j.bone.2010.01.374. Epub 2010 Jan 25.
10
A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.一种抑制骨吸收的新方法:组织蛋白酶K的外位点抑制剂
Br J Pharmacol. 2016 Jan;173(2):396-410. doi: 10.1111/bph.13383. Epub 2015 Dec 16.

引用本文的文献

1
Non-coding RNA modulation in osteoclasts and its implications for osteoblast lineage cell behavior in a co-culture system.破骨细胞中的非编码RNA调控及其在共培养系统中对成骨细胞谱系细胞行为的影响
Cell Commun Signal. 2025 Aug 12;23(1):370. doi: 10.1186/s12964-025-02324-7.
2
Cathepsin K inhibitors promote osteoclast-osteoblast communication and engagement of osteogenesis.组织蛋白酶K抑制剂可促进破骨细胞与成骨细胞的交流以及成骨作用。
JBMR Plus. 2025 May 6;9(8):ziaf079. doi: 10.1093/jbmrpl/ziaf079. eCollection 2025 Aug.
3
Isolation and Generation of Osteoclasts.

本文引用的文献

1
HBP/O-GlcNAcylation Metabolic Axis Regulates Bone Resorption Outcome.高血压/ O-连接N-乙酰葡糖胺糖基化代谢轴调节骨吸收结果。
J Dent Res. 2023 Apr;102(4):440-449. doi: 10.1177/00220345221141043. Epub 2023 Feb 7.
2
Osteoclasts, Master Sculptors of Bone.破骨细胞,骨骼的雕刻大师。
Annu Rev Pathol. 2023 Jan 24;18:257-281. doi: 10.1146/annurev-pathmechdis-031521-040919. Epub 2022 Oct 7.
3
Mechanisms of bone resorption.骨吸收的机制
破骨细胞的分离与生成
Methods Mol Biol. 2025;2885:23-49. doi: 10.1007/978-1-0716-4306-8_2.
4
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers.组织蛋白酶:肿瘤生态系统中克服癌症的新兴靶点。
Semin Cancer Biol. 2025 Jul;112:150-166. doi: 10.1016/j.semcancer.2025.04.001. Epub 2025 Apr 12.
5
Proteins and DNA Sequences Interacting with Tanshinones and Tanshinone Derivatives.与丹参酮及丹参酮衍生物相互作用的蛋白质和DNA序列
Int J Mol Sci. 2025 Jan 20;26(2):848. doi: 10.3390/ijms26020848.
Bone. 2022 Oct;163:116499. doi: 10.1016/j.bone.2022.116499. Epub 2022 Jul 21.
4
Novel insights into the coupling of osteoclasts and resorption to bone formation.骨细胞与吸收耦联到骨形成的新见解。
Semin Cell Dev Biol. 2022 Mar;123:4-13. doi: 10.1016/j.semcdb.2021.10.008. Epub 2021 Oct 30.
5
Inadequate response to treatment reveals persistent osteoclast bone resorption in osteoporotic patients.治疗反应不足揭示了骨质疏松症患者持续的破骨细胞骨吸收。
Bone. 2021 Dec;153:116167. doi: 10.1016/j.bone.2021.116167. Epub 2021 Sep 4.
6
The Mechanism Switching the Osteoclast From Short to Long Duration Bone Resorption.将破骨细胞从短期骨吸收转换为长期骨吸收的机制。
Front Cell Dev Biol. 2021 Mar 30;9:644503. doi: 10.3389/fcell.2021.644503. eCollection 2021.
7
Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption.在RANKL刺激的骨吸收过程中,破骨细胞通过骨形态细胞进行循环利用。
Cell. 2021 Apr 1;184(7):1940. doi: 10.1016/j.cell.2021.03.010.
8
Increased Bone Resorption during Lactation in Pycnodysostosis.成骨不全症患者哺乳期骨吸收增加。
Int J Mol Sci. 2021 Feb 11;22(4):1810. doi: 10.3390/ijms22041810.
9
Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons.类风湿关节炎中的骨质疏松:危险关联。
Front Med (Lausanne). 2020 Nov 23;7:601618. doi: 10.3389/fmed.2020.601618. eCollection 2020.
10
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals.唑来膦酸对不同个体来源的破骨细胞的作用效果并不相同。
JBMR Plus. 2020 Sep 29;4(11):e10412. doi: 10.1002/jbm4.10412. eCollection 2020 Nov.